Clinuvel Pharmaceuticals Limited   Report issue

Contributed to NME For profit Phase 3
Founded: Melbourne Australia (1987)

Organization Overview

First Clinical Trial
2007
NCT00472901
First Marketed Drug
2019
afamelanotide (Scenesse)
First NDA Approval
2019
afamelanotide (Scenesse)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clinuvel Europe Limited | Clinuvel Pharmaceuticals Limited | CLINUVEL PHARMACEUTICALS LTD | CLIVUNEL INC